Settlement reached in national class-action lawsuit over drug Rexulti: law firm

Class-Action Lawsuit Over Rexulti Drug Reaches $4.75 Million Settlement

Lawyers involved in a class-action lawsuit over the drug Rexulti have announced a $4.75 million settlement on behalf of patients and their families. The lawsuit pertained to individuals in Canada who were prescribed Rexulti between Feb. 16, 2017 and the present day and experienced compulsive behaviors or impulse-control disorders.

Rexulti: An Antipsychotic Medication

Rexulti is an antipsychotic medication commonly used to treat schizophrenia and depression.

A notice released by Toronto law firm Rochon Genova stated that Quebec Superior Court has not yet made a determination on the merits of the claims, and the settlement is a compromise without any admission of liability or wrongdoing on the part of the defendants. The national class action against the manufacturers was authorized by Quebec Superior Court in 2024.

Lawyers involved in the case will be presenting the settlement for approval before the court in Montreal on Oct. 31, 2025.

This report by The Canadian Press was originally published on Aug. 23, 2025.

The Canadian Press